drugset

drugset / Trial / NCT03502746

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

NCT03502746 ↗

Phase 2 Terminated 34 enrolled Arkadiusz Z. Dudek, MD Bristol-Myers Squibb · collab Eli Lilly and Company · collab HealthPartners Institute Regions Cancer Care Center · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the combination of Nivolumab and Ramucirumab in patients with previously-treated mesothelioma.

Timeline

Start: 2018-06-26
Primary completion: 2022-05-11
Completion: 2023-11-09

Outcome

Missed primary endpoint

Stopped: “IRB Study Closure”

paper The primary end point of 40% ORR was not reached. PMID 38046376 ↗

Publications

Dudek AZ, Xi MX, Scilla KA, Mamdani H, Creelan BC, Saltos A, Tanvetyanon T, Chiappori A. Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. JTO Clin Res Rep. 2023 Oct 12;4(12):100584. doi: 10.1016/j.jtocrr.2023.100584. eCollection 2023 Dec.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	240 mg	Intravenous
Subject	Ramucirumab	Monoclonal antibody	8 mg/kg	Intravenous

Indications